Patents Assigned to Les Laboratoires Servier
  • Patent number: 11833162
    Abstract: Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: December 5, 2023
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: Jérôme-Benoît Starck, Didier Durand, I-Jen Chen, Arnaud Le Tiran, Jean-Claude Ortuno, Miklós Nyerges, Melinda Ligeti, Imre Fejes
  • Patent number: 11807688
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 7, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Torben Gjetting, Trine Lindsted, Anton Willer, Anne Worsaae, Maria Carlsen Melander, Janus Schou Jakobsen, Randi Westh Hansen
  • Publication number: 20230227573
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 20, 2023
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Michael Monrad GRANDAL, Torben GJETTING, Johan LANTTO, Janus Schou JAKOBSEN, Randi Westh HANSEN, Camilla FRÖHLICH
  • Patent number: 11634500
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 25, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Michael Monrad Grandal, Torben Gjetting, Johan Lantto, Janus Schou Jakobsen, Randi Westh Hansen, Camilla Fröhlich
  • Patent number: 11613753
    Abstract: Using chemical proteomics with a potent unique irreversible inhibitor, inventors found that major brain tubulin carboxypeptidase (TCP) is a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). VASH1 and its homologue vasohibin-2 (VASH2), when complexed with SVBP, exhibit robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Accordingly inventors are the first to identify the enzymatic activity of vasohibin and vasohibin/SVBP complex. Knock down of vasohibins or SVBP in cultured neurons results in a marked reduction of tyrosinated ?-tubulin levels and onset of severe differentiation defects. Furthermore, knock down of vasohibins disrupts neuronal migration in developing mouse neocortex. These results establish vasohibin/SVBP complexes as TCP enzymes.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 28, 2023
    Assignees: LES LABORATOIRES SERVIER, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Annie Andrieux, Marie-José Moutin, Christophe Bosc, Chrystelle Aillaud, Leticia Peris, Philippe Delagrange
  • Patent number: 11512062
    Abstract: Process for the industrial synthesis of the compound of formula (I):
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 29, 2022
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Louis-Philippe Beauregard, Martial Bertrand, Pascall Giguere, Christophe Hardouin, Bruno Schiavi
  • Patent number: 11466023
    Abstract: A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 11, 2022
    Assignees: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: Andrew Wei, Donia Moujalled, Giovanna Pomilio, Olivier Geneste, Ana Leticia Maragno
  • Publication number: 20220211718
    Abstract: The invention relates to a Bcl-2 inhibitor for use in the treatment of a Bcl-2 mediated cancer carrying at least 1, 2, 3, 4, 5 or all of the following mutations: (i) Gly101Val; (ii) Asp103Tyr; (iii) Asp103Val; (iv) Asp103Glu; (v) Arg129Leu and (vi) Ala113Gly; wherein the Bcl-2 inhibitor is N-(4-hydroxyphenyl)-3-{6-[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide (Compound A) or 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-iH-pyrrole-3-carboxamide (Compound B), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 11, 2020
    Publication date: July 7, 2022
    Applicants: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: James Brooke MURRAY, Frèdéric COLLAND, Audrey CLAPERON
  • Publication number: 20220203260
    Abstract: Disclosed is a removable containment device for a rotary evaporator, comprising: a first end (12) for sealed connection to a rotation shaft (3) of the rotary evaporator (1); a second end (13) for sealed connection to a container (2) for receiving a mixture to be evaporated; and a body (11) in fluid connection with the first and second sealed connection ends (12, 13) comprising a valve system (14) for the selective passage between the first and second ends (12, 13) of the evaporating constituent of the mixture to be evaporated.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 30, 2022
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Jean-Baptiste Gandar, Christophe Besseyre, Bruno Aubry, Samuel Lapert
  • Publication number: 20220195035
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 23, 2022
    Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 11332472
    Abstract: Compounds of formula (I): wherein R1, R2, R3, B, W, Z, m and n are as defined in the description.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 17, 2022
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: András Kotschy, Csaba Wéber, Attila Vasas, Árpád Kiss, Balázs Molnár, Ágnes Strofek, Vilibald Kun, James Brooke Murray, Alba Macias, Elodie Lewkowicz, Maïa Chanrion, Lisa Ivanschitz, Olivier Geneste
  • Patent number: 11058689
    Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: July 13, 2021
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: Arnaud Le Tiran, Thierry Le Diguarher, Jérôme-Benoît Starck, Jean-Michel Henlin, Anne-Françoise Guillouzic, Guillaume De Nanteuil, Olivier Geneste, Imre Fejes, János Tatai, Miklós Nyerges, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Didier Durand
  • Patent number: 11046681
    Abstract: Compounds of formula (I): wherein R1, R2, R3, n and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic and/or anti-proliferative agents.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 29, 2021
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: András Kotschy, Csaba Wéber, Attila Vasas, Balázs Molnár, Árpád Kiss, Alba Macias, James Brooke Murray, Elodie Lewkowicz, Olivier Geneste, Maïa Chanrion, Didier Demarles
  • Patent number: 11028070
    Abstract: Compound of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, t, p, p?, q, and q? are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic agent.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: June 8, 2021
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Claire Walmsley, Mark Dodsworth, Johannes W. G. Meissner, Paul Brough, Imre Fejes, János Tatai, Miklós Nyerges, András Kotschy, Zoltán Szlávik, Olivier Geneste, Arnaud Le Tiran, Thierry Le Diguarher, Jean-Michel Henlin, Jérôme-Benoît Starck, Anne-Françoise Guillouzic, Guillaume De Nanteuil
  • Patent number: 10722466
    Abstract: The invention relates to a pharmaceutical liposomal composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl) propanoic acid, referred to herein as ‘Compound A’, or a pharmaceutically acceptable salt thereof. More specifically the invention relates to a liposomal vehicle, an organic concentrate composition comprising Compound A, and a pharmaceutical composition for parenteral administration comprising liposomes and Compound A. Furthermore, the invention relates to the use of such compositions for the treatment of cancer. ‘Compound A’ as used herein includes all enantiomers, diastereoisomers, and atropisomers thereof, or mixtures thereof, and also optionally includes the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: July 28, 2020
    Assignees: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: Peter Wessels, Henricus Tiemessen, Paolo De Marco, Malika Larabi, Christiane Schiedel, Marina Gurina
  • Patent number: 10689364
    Abstract: Compounds of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, T, p, p?, q, and q? are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: June 23, 2020
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Claire Walmsley, Mark Dodsworth, Johannes W. G. Meissner, Paul Brough, Imre Fejes, János Tatai, Miklós Nyerges, András Kotschy, Zoltán Szlávik, Olivier Geneste, Arnaud Le Tiran, Thierry Le Diguarher, Jean-Michel Henlin, Jérôme-Benoît Starck, Anne-Françoise Guillouzic, Guillaume De Nanteuil
  • Patent number: 10662173
    Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, T and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 26, 2020
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: Patrick Casara, Thierry Le Diguarher, Jean-Michel Henlin, Jérôme-Benoît Starck, Arnaud Le Tiran, Guillaume De Nanteuil, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Claire Walmsley, Christopher John Graham, Stuart Ray, Daniel Maddox, Simon Bedford
  • Patent number: 10654849
    Abstract: Compounds of formula (I): wherein R1, R2, J, K, L, n and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic and/or anti-proliferative agents.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 19, 2020
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: András Kotschy, Csaba Wéber, Attila Vasas, Balázs Molnár, árpád Kiss, Alba Macias, James Brooke Murray, Elodie Lewkowicz, Olivier Geneste, Mäia Chanrion, Didier Demarles, Lisa Ivanschitz
  • Patent number: 10654878
    Abstract: Compounds of formula (I) wherein: Ak1 represents an alkyl chain, X represents —(CH2)m—, —CH(R)—, —N(R)—, —CH2—N(R)—, —N(R)—CH2— or —CH2—N(R)—CH2—, m and R are as defined in the description, R1 and R2 each represent H when X represents —(CH2)m—, —CH(R)—, —N(R)—, —CH2—N(R)— or —N(R)—CH2—, or together form a bond when X represents —CH2—N(R)—CH2—, R3 represents NH2, Cy-NH2, Cy-Ak3-NH2 or piperidin-4-yl, Cy and Ak3 are as defined in the description, R4 and R5, which may be identical or different, each represent H or F, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating conditions requiring a TAFIa inhibitor.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 19, 2020
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Philippe Gloanec, Arnaud-Pierre Schaffner, Patricia Sansilvestri-Morel, Alain Rupin, Philippe Mennecier, Marie-Odile Vallez
  • Patent number: 10618909
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: April 14, 2020
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: Balázs Bálint, Márton Csékei, Zoltán Szabó, Zoltán Szlávik, András Kotschy, Maïa Chanrion, Olivier Geneste, I-Jen Chen, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Levente Ondi, Ágnes Proszenyák